Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 359 participants.

Also called NCT04668144

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 359 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04668144
Other papers using this trial's data
  • Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study JACC. Cardiovascular interventions, 2023-10-23 DOI, PubMed 37609698

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04668144. Randomized; no masking; primary purpose treatment. Start 2021-02-18 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-03-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
Acronym
SWAP-6
Condition
Acute Coronary Syndrome
Intervention (Drug)
Cangrelor
Intervention (Drug)
Prasugrel
Lead sponsor
University of Florida (class: other)
Collaborator
Scott R. MacKenzie Foundation (class: other)

Record details

Record id
cardio:ct-nct04668144
Content hash
1086b6989f9a3e3b54cfaefd1b123b85f88e33c2a7bcb4942db57eb48dd9ee22